ReviewAnnals of medicine2022
Comorbidities of sarcoidosis.
Review in Annals of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 52 citations in OpenAlex.
- Treatable traits approach for personalised management of sarcoidosis.BMJ open respiratory research · 2026Review
- Bone involvement in sarcoidosis: Insights from a multicentre Italian cohort.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Kidneys in the crossfire: insights into renal sarcoidosis.BMC nephrology · 2026Observational
- Redefining Cardiac Sarcoidosis with Advanced Imaging and Therapeutic Strategies.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Global and Chinese trends in disease burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2021 with projections to 2040: a COVID-19 impact analysis based on the Global Burden of Disease Study 2021.Journal of thoracic disease · 2026Article
- Clinical Insights and Diagnostic Challenges of Pulmonary Lophomoniasis in a Sarcoidosis Patient: A Case Report.Case reports in pulmonology · 2026Article
- Editorial: Unlocking the microbial code: potential role in sarcoidosis pathogenesis and treatment.Frontiers in immunology · 2026Article
- Asthma in Patients With Confirmed Pulmonary Sarcoidosis.Canadian respiratory journal · 2026Review
- Global, regional, and national burden of chronic respiratory diseases,1990-2021 and predictions to 2035: analysis of data from the global burden of disease study 2021.Annals of medicine · 2025Article
- Neuropsychiatric manifestations of sarcoidosis.Annals of medicine · 2025Review
- Clinical and Demographic Characteristics of Oral Sarcoidosis: A Systematic Review of Case Reports and Case Series.Journal of clinical medicine · 2025Review
- Concurrent Pulmonary Sarcoidosis and Carcinomatous Lymphangitis.Internal medicine (Tokyo, Japan) · 2025Article
- Sarcoidosis in the Genomic Era: From Genetic Drivers to Tailored Therapies.Current allergy and asthma reports · 2025Review
- Use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis: A systematic literature review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Evaluation of obstructive sleep apnea syndrome in sarcoidosis patients: a clinical and polysomnographic analysis.Sleep & breathing = Schlaf & Atmung · 2025Observational
- Response to corticosteroids and alternative therapies in sarcoidosis-related hypercalcemia: A guideline-lacking retrospective analysis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Sarcoidosis: molecular mechanisms and therapeutic strategies.Molecular biomedicine · 2025Review
- Article
- Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease.Scientific reports · 2025Article
- Shifting temporal trends and disparities in sarcoidosis mortality in the United States: A retrospective analysis from 1999 to 2020.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is a heterogeneous disease, which can affect virtually every body organ, even though lungs and intra thoracic lymph nodes are almost universally affected. The presence of noncaseating granulomas is the histopathological hallmark of the disease, and clinical picture depends on the organs affected. Data about interaction between sarcoidosis and comorbidities, such as cardiovascular and pulmonary diseases, autoimmune disorders, malignancy and drug-related adverse events are limited. Several lung conditions can be associated with sarcoidosis, such as pulmonary hypertension and fibrosis, making it difficult sometimes the differentiation between complications and distinctive pathologies. Their coexistence may complicate the diagnosis of sarcoidosis and contribute to the highly variable and unpredictable natural history, particularly if several diseases are recognised. A thorough assessment of specific disorders that can be associated with sarcoidosis should always be carried out, and future studies will need to evaluate sarcoidosis not only as a single disorder, but also in the light of possible concomitant conditions.Key messagesComorbidities in sarcoidosis are common, especially cardiovascular and pulmonary diseases.In the diagnostic workup, a distinction must be made between sarcoidosis-related complaints and complaints caused by other separate disorders. It can be very difficult to distinguish between complications of sarcoidosis and other concomitant conditions.The coexistence of multiple conditions may complicate the diagnosis of sarcoidosis, affect its natural course and response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.